Sandoz receives European Commission approval for Zessly (infliximab) in gastroenterological, rheumatological and dermatological diseases
Sandoz receives European Commission approval for Zessly (infliximab) in gastroenterological, rheumatological and dermatological diseases
- European Commission's (EC) approval based on comprehensive data package confirming that Zessly? matches safety, efficacy and quality of reference medicine
- Biosimilars such as Zessly enable earlier patient access to important medicines and positively impact healthcare systems
- Zessly is the third EC approval for a Sandoz biosimilar in 12 months
Novartis Media Relations Central media line: +41 61 324 2200 E-mail: media.relations@novartis.com | |
Eric Althoff Novartis Global Media Relations +41 61 324 7999 (direct) +41 79 593 4202 (mobile) eric.althoff@novartis.com | |
Chris Lewis Sandoz Global Communications +49 8924 476 1906 (direct) +49 174 244 9501 (mobile) chris.lewis@sandoz.com | Michelle Bauman Sandoz Global Communications +1 973 714 8043 (mobile) michelle.bauman@sandoz.com |
Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: investor.relations@novartis.com |